All News
EULAR 2022 – Day 3 Report
By now, those of us attending the meeting know how to find a free coffee or sprite, have found comfortable meeting nooks and know our way around! PAnd congrats to you virtual Rheums for mastering the multi-screen, multitask simultaneous consumption posters, tweets and oral abstract presentations.
Read Article
So what diet to follow with autoimmunity in mind?
So many, all with different instructions.
Let’s concentrate on where they agree:
yes to fruits & vegetables
no to emulsifiers & processed foods
#EULAR2022 @RheumNow https://t.co/I9abweQOyZ
David Liew drdavidliew ( View Tweet)
Amigues et al. Zoledronate related ONJ. French pharmacovigilance database. Rare with rheumatic (vs onc) use but higher than with risedronate or alendronate. Incidence 9.6 vs 2 vs 5.1 /100000 @RheumNow #EULAR2022 OP0240 https://t.co/SCYiyJF76S
Links:
Richard Conway RichardPAConway ( View Tweet)
Mease et al. Minimal radiographic progression in patients treated with IL-23i guselkumab over 2 years. This trial enriched for high-risk radiographic progression. Clinical response associated with less radiographic progression. @RheumNow #EULAR2022 POS1035 https://t.co/1C21MNVpV8
Richard Conway RichardPAConway ( View Tweet)
Fornaro et al. GISEA registry. No effect of reduced eGFR<60 on drug survival HR 0.9 (95%CI 0.7-1.2) @RheumNow #EULAR2022 POS0634 https://t.co/TjjxgCCz0Z
Richard Conway RichardPAConway ( View Tweet)
#OP0286 #EULAR2022 With no licensed therapy, we need a better and responsive outcome measure. Using data-driven method, SJÖGREN’S TOOL FOR ASSESSING RESPONSE (STAR) has been developed. This will be evaluated in NECESSITY RCTs across Europe @RheumNow https://t.co/U5Aj6bwWBy
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Top Influencers of #EULAR2022: @RichardPAConway @RheumNow @eular_org @EMEUNET @rheum_cat @ARD_BMJ @ProftDr More 📊 https://t.co/fUfohEZAoX
Symplur Hashtags healthhashtags ( View Tweet)
#ClinicalPearl? #METEOR is a multi-country ~40K database of #rheumatoid arthritis. @eular_org #EULAR2022- found YOUNGER age of onset of RA close to equator, opposite to low Vitamin D if more NORTH /less sun and MORE #multiple #sclerosis. ?From low age at equator OP0035 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Padoan et al. Cancer increased in EGPA. SIR 1.99 (1.22-3.08) all cancer, 1.86 (0.98-2.75) exc. NMSC. Higher ANCA+ 2.42 (1.30-4.16) and CYC treated 2.42 (1.11-4.60). 60% within years 1-5 post diagnosis @RheumNow #EULAR2022 POS0838 https://t.co/9GDLsBknO6
Richard Conway RichardPAConway ( View Tweet)
Frisell et al. Safety b/tsDMARDs from 10 years ARTIS. There is a mass of interesting data here, look at that figure! Higher rates of discontinuation due to AEs for tofa, bari, sari, rituximab. May be explained by chanelling and residual confounding @RheumNow #EULAR2022 POS0637 https://t.co/KrspU6c9Cs
Richard Conway RichardPAConway ( View Tweet)
Dr Gossec et al. Multidomain indices show consistent benefit when applied to IL23i guselkumab COSMOS trial. I like MDA (because its simple and so am I) so showing that. But same benefits seen in DAPSA, PASDAS, mCPDAI, GRACE, PsARC. @RheumNow #EULAR2022 POS1038 https://t.co/EU2VHpEGc3
Richard Conway RichardPAConway ( View Tweet)
Characteristics assoc outcomes PsO/PsA/axSpA @pedrommcmachado @rheum_covid bDMARDS, NSAIDs assoc better outcomes. Usually culprits assoc worse outcomes (age, CVD etc), and also disease activity and steroids @RheumNow #EULAR2022 OP0249 https://t.co/siLdQVj2jb https://t.co/BmdwspDhsG
Links:
Richard Conway RichardPAConway ( View Tweet)
What drives residual pain improvement in #JAKi treated pts? Dunno but #Baricitinib and #Sarilimab showed better pain decrease vs placebo and #Adalimumab. #OP0052 showed both #Tofacitinib & Adalimumab reduced pain more than placebo in PsA & RA if in remission @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
Mease et al. IL23i guselkumab on axial outcomes in PsA at 2 years in DISCOVER-2. Guselkumab improves BASDAI, mBASDAI, spinal pain, ASDAS to week 100. Still trying to get my head around this seeming to work for PsA spinal disease but not axSpA @RheumNow #EULAR2022 POS1037 https://t.co/LZgXEl6Ohl
Richard Conway RichardPAConway ( View Tweet)
Babies! Safety and Outcomes Data on Pregnancies
#EULAR2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye...
https://t.co/ulQIo2gdlO https://t.co/dpoMd5Wbah
Links:
Dr. John Cush RheumNow ( View Tweet)
Getting Real on PMR
Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022
https://t.co/BCdOTzeOHx https://t.co/VO95uHaKxg
Links:
Dr. John Cush RheumNow ( View Tweet)
Full circle. I met Prof D Isenberg at my first EULAR Congress 10 years ago. He welcomed a strangers request to come for Rheumatology training at UCLH with open arms. A kind, generous soul. My heart is full whenever we meet.❤️ https://t.co/yvwYyDKRD6
Dzifa Dey RheumtoBloom ( View Tweet)
Looks like I’m not the only one who doesn’t let the absence of synovitis stop me from sometimes treating high-risk clinically suspect arthralgias i.e. ‘very early early RA’
The truth comes out in anonymous surveys!
#EULAR2022 @RheumNow https://t.co/BqTLy4HBWR
David Liew drdavidliew ( View Tweet)
A bit late but finally managed to get a proper Danish pastries on Day 3 in 🇩🇰🥳 #EULARpastrychallenge 🥐 #EULAR2022 https://t.co/PhmOd3ylzb
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Interesting stats - over 4400 #EULAR2022 tweets yesterday but only half that number today. #ConferenceFatigue @RheumNow https://t.co/HILdrb5Wkd
TheDaoIndex KDAO2011 ( View Tweet)
